Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain

Executive Summary

More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.


Related Content

Pharma And Intermediaries Split Money Spent On Drugs, Study Shows
Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma
What's At Stake: Biopharma Profit Growth Reliant On Price Increases
Best Defense Is Good Offense: PhRMA Wants PBMs To 'Share The Savings'
Cost Sharing Fight: PhRMA Says Insurance Design Is Real Pricing Culprit
Trump, Congress And The Search For Common Ground On Drug Pricing
Drug Cost Blame Game: Payers’ Contribution To Prices Getting More Attention
How Many Pricing Hearings Add Up To Action On Pricing Transparency?
Industry’s Rebate Arms Race: Securing Market Access At A Cost
Price Concessions By Manufacturers To Payers Rose Sharply In 2015


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts